Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

Could a new device called a portable neuromodulation stimulator (PoNS) help improve your mobility and balance with multiple sclerosis? PoNS is a device that delivers mild electrical pulses to two ...

Helius Medical Technologies, Inc. has announced that Aetna Healthcare has authorized payment for the PoNS Device at an out-of-network negotiated price of $18,350, making Aetna the third major ...

Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network ...

The PoNS device is a non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece to improve balance and gait. It is FDA-authorized as a short-term treatment for ...

This figure reflects the typical adjusted price for out-of-network claims and represents an important validation of both the clinical need and the overall value of the PoNS Device. A Breakthrough ...

Helius Medical Technologies will present significant new study results at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting, showcasing the sustained efficacy of its PoNS® device.

CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers ...

Depending on the individual’s deductible and out-of-pocket costs, this claim may not result in an immediate PoNS Device sale. About the PoNS Device and PoNS Therapy The Portable Neuromodulation ...